Maravai LifeSciences, Inc., a global provider of life sciences reagents and services to researchers and biotech innovators, announced that it has completed the previously announced acquisition of Officinae Bio ‘s DNA and RNA business. This acquisition combines Officinae Bio’s AI-powered mRNA design platforms with Maravai and TriLink BioTechnologies ‘ leading drug manufacturing capabilities , providing customers with comprehensive expertise and novel technologies for rapid, calculated progression through the mRNA sequence optimization phase to clinical testing and commercial manufacturing.
Based in Venice, Italy, Officinae Bio’s proprietary digital platform accelerates the prototyping of mRNA drug candidates and enables the rapid testing of different combinations of capping analogues, chemical modifications and sequence designs to advance clients’ research programs into the clinical phase.
Also Read: Alamar Biosciences Launches NULISAqpcr™ Custom Assay Kit for Biomarker Research
“We are very excited to bring Officinae into the Maravai family, where their talented team will expand our TriLink discovery business with cutting-edge AI-driven sequence design and seamless e-commerce. Together, we aim to advance the next-generation medicines space in mRNA and CRISPR with best-in-class chemistry, processes and proprietary technologies such as CleanCap ® analogues,” said Trey Martin, CEO of Maravai LifeSciences. “This acquisition also marks our first step into the very important European market with a manufacturing presence. This market access will fuel our growth in the post-pandemic era across multiple product lines.”
Davide De Lucrezia, Chief Executive Officer and co-founder of Officinae Bio, commented: “By working with Maravai and TriLink, we can expand our expertise in AI-driven tools to help more customers accelerate their development and identify candidate sequences with fewer errors. Combined with TriLink’s decades of experience in chemical and biological manufacturing, we can now optimize the design-build-test-learn cycle for our customers.”
Davide will continue to lead the Officinae Bio team, which is now a business unit within Maravai’s nucleic acid production segment.
Source: Businesswire